



ASX ANNOUNCEMENT

23 February 2024

APPOINTMENT OF DIRECTOR

CARDIEX Limited (ASX: CDX) (**CARDIEX**, the **Company**) is pleased to announce the appointment of Mr. Charlie Taylor as an independent Non-executive Director, effective 1 March 2024. Mr. Taylor is a recently retired Senior Partner of McKinsey with over 30 years' experience in local and international advisory for both private and public sector healthcare organizations. He joins the Board as an Australian based Director.

Prior to his retirement, Mr. Taylor led the Health and Public Sector practice at McKinsey. He has advised many Australian and global private and public sector healthcare organizations on topics including strategy, digital health, operations and growth transformation, global expansion and supply chains, mergers and acquisitions, and board governance. Charlie has also initiated multi-year research efforts on healthcare, COVID response, and productivity and innovation. He has also published multiple research articles and reports on global healthcare reform.

Charlie's current roles include Non-executive Director of Healius (a leading Australian health diagnostics company), a part-time senior board advisor at McKinsey for the Health and Public Sector practice, a Director of MacLauglin River Pastoral Company, a member of the strategic advisory committee For Purpose Investment Partners, and Chair of the NSW Innovation and Productivity Commission.

As Non-executive Director, Mr. Taylor will be remunerated from the Non-executive Director's remuneration pool.

CARDIEX's Executive Chairman, Niall Cairns commented:

"We welcome Charlie to the Board of CARDIEX. Charlie brings significant experience to the Board in consumer health technologies, global healthcare policy, and corporate strategy and governance. Charlie's diverse experience in guiding growth and transformation across multiple industry sectors across his career is certain to be of value to us as we enter this next stage of growth."

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About CARDIEX

CARDIEX's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CARDIEX is listed on the Australian Stock Exchange ("CDX").